Company news - Timeline

22/05/2019 Micar21

Our manuscript "Discovery of GlyT2 Inhibitors using Structure-based Pharmacophore Screening and Selectivity studies by FEP+ Calculations" accepted in ACS Med. Chem. Letters

07/03/2019 Micar21

Micar Innovation (Micar21) is the winner of а prestigious award: "Investor of the year 2018” success startup

Deputy Minister of Ministry of Economy of the Republic of Bulgaria Mr. Borisov handed award: "Investor of the year 2018" success startup to Dimitar Dimitrov ...

12/02/2019 Micar21

Micar Innovation ( listed in Deep Knowledge Analytics report:

AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape / 2018 Q2 and 2018 Q4 ...

08/02/2019 Micar21


The President of the Republic of Bulgaria Mr. Rumen Radev handed Excellence in Innovation label to Filip Fratev. ...

06/12/2018 Micar21

Micar Innovation (Micar21) is the winner of а prestigious award for “Innovative startup enterprise of the year” 2018

The National Competition "Innovative Enterprise of the Year" annually awards Bulgarian enterprises with successfully implemented innovative products, processes, services and practices on the Bulgarian and world markets ...

05/12/2018 Micar21

Micar Innovation is One of 250 Companies listed in Roots Analysis Study on "Computer-Aided Drug Discovery Services Market 2018-2030"

Micar Innovation is a "factory" for discovering new drug molecules. The company has found a niche to create big public impact ...

18/10/2018 Micar21

Micar Innovation (Micar21) listed in A Map of AI Startups in Drug Discovery:

This map below is to illustrate the diversity of use cases for AI adoption in a typical pharmaceutical R&D process. . ....

Visit Map of AI Startups in Drug Discovery:
27/08/2018 Micar21

Micar Innovation (Micar21) listed as a Emerging Players in study on 'Computer-Aided Drug Discovery Services Market, 2018-2030 - Roots Analysis

As a result, players offering novel in silico drug discovery services ...

01/08/2018 Micar21

Micar Innovation (Micar21) is part of organizers of new Bulgarian Health & Life Sciences cluster

The Bulgarian Health & Life Sciences cluster ecosystem comprises several stakeholders from academia, the public sector, and the private sector. The principal idea is to facilitate open collaboration and to accelerate innovation by bringing together various partners able to contribute to the needs of the health care sector. ....

Visit new Bulgarian Health & Life Sciences cluster
01/08/2018 Micar21

Micar Innovation (Micar21) listed in new project of Bulgarian Ministry of Economy & Besco

Innovative Bulgarian companies & organizations. Some of these companies are global leaders in their own category, some are fresh startups. ....

Visit project:
21/05/2018 Micar21

Publication for Micar Innovation in

CIDIC (European Centre for Economic, Academic and Cultural Diplomacy) - Diplomatic, Economic, Academic, and Cultural (DEAC) mission to Sofia, 23-26 April 2018, in cooperation with UNICA and BACES, VUB-Brussels Diplomatic Academy and Diplomatic World

MICAR INNOVATION is a drug discovery factory. The company has found a niche where it is able to create a large societal impact by improving the quality of life through new blockbuster drug molecules for a large class of diseases....

Read More
24/04/2018 Micar21

Micar Innovation (Micar21) has been awarded a “European CIDIC Award”

The CIDIC jury, composed of its board of directors, professors of the Vrij Universiteit Brussel (VUB), representatives of the Bulgarian Embassy in Brussels, is pleased to inform that Micar Innovation (Micar21) has been awarded a “European CIDIC Award”. ....

Read More
23/04/2018 Micar21

Micar Innovation (Micar21) has invitation for Pioneers'18 which will be held on May 24-25, 2018 in Vienna

Pioneers'18 which will be held on May 24-25, 2018 in Vienna - the ultimate meeting point for 2500 bold, pioneering entrepreneurs to look into the future and beyond. A global community of selected startups, executives and investors join forces under the roof of the 500-year-old Hofburg Imperial Palace in Vienna to redefine human tech frontiers.

21/04/2018 Micar21

Micar Innovation - one of the top 20 startups on ThePitcher 2018

This year more than 970 startups from 20 different countries applied for The Pitcher 2018 event. The number of great ideas, extraordinary teams and unique pitch decks, which all applicants presented, pleasantly surprised and deeply inspired us. Unfortunately, not everyone could make it to the finals. After a long and very difficult evaluation process, we are ready and very happy to announce the top 20 startups that will take by storm The Pitcher 2018 stage on April 21st. Meet The Pitcher 2018 TOP 20!

24/02/2018 Micar21

Micar Innovation (Micar21) is part of Consulting Cluster VERITAS

Consulting Cluster VERITAS: The success of high performance cluster is in large part, due to people forming quality relationships and networking to achieve results - a chemistry. These linkages are informal and are supported by more formal organizations, institutions. ....

Visit cluster:
22/02/2018 Micar21

An Improvement of the Free Energy Perturbation (FEP+) Sampling Protocol in Case of Flexible protein Ligand Binding Sites

Recent improvements to free energy perturbation (FEP) calculations, especiallyFEP+, established their utility for pharmaceutical lead optimization. However, to dateFEP has typically been helpful only when (1) high-quality X-ray data is available and(2) the target protein does not undergo significant conformational changes. ....

Read More
14/01/2018 Micar21

Prediction of Accurate Binding Modes using Combination of classical and accelerated Molecular dynamics and Free Energy Perturbation Calculations: An Application to Toxicity Studies

Estimating the correct binding modes of ligands in protein-ligand complexes is not only crucial in the drug discovery process, but also for elucidating potential toxicity mechanisms. In the current paper, we discuss and demonstrate a computational modelling protocol using the combination of docking, classical (cMD) and accelerated (aMD) molecular dynamics and free energy perturbation (FEP+ protocol) for identification of the binding modes of selected perfluorocarboxyl acids (PFCAs) in the PPARγ nuclear receptor ....

Read More
31/10/2017 Micar21

Combination of Structural based Pharmacophore and Docking Virtual Screens: An Efficient Structure-based Protocol for Lead Identification

The structural and ligand base In silico screens are of great help during the drug discovery nowadays and their combination has been shown to provide better results than using a single approach ....

Read More
17/10/2017 Micar21

Micar Innovation (Micar21) TOP 8 BioTech Award by Delta Ventures and the TOP 50 of the 2018 Startup World Cup & Summit Regional Finals!

Congratulation! We just chose your startup, Micar 21, into the competition Startup World Cup & Summit/ categorie: BioTech by Delta Ventures: Startup World Cup & Summit will take place on October 17th at Palác Lucerna and its unique surroundings.. ....

Read More
27/09/2017 Micar21

Micar Innovation (Micar21) named Best Biotech Startup of the year 2017 in CEE - Bulgaria National Winners

On the 4th edition of the Central European Startup Awards finals, competition that includes national finalists from 10 countries in Central and Eastern Europe, Micar Innovation (Micar21) was named Best Biotech Startup of the year in CEE - Bulgaria National Winners. ....

Read More
19/02/2016 Micar21

PPARγ helix 12 exhibits an antagonist conformation

Although the peroxisome proliferator-activated receptor γ (PPARγ) is one of the most studied nuclear receptors (NR), it is still unknown whether its activation helix (helix 12, H12) could exhibit an antagonist conformation as previously demonstrated for most of the NRs. ....

Read More
12/02/2016 Micar21

PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: A case study

The structural and dynamical properties of PPARγ receptor in a complex with either partial or full agonists have been intensively studied but little is known about the receptor antagonistic conformation. A composition of microsecond accelerated molecular ....

Read More
25/09/2015 Micar21

Try our outsourcing services!

To the end of March 2016 our company will provide outsourcing services that are not charged through the initial phase of any project! We offer three weeks evaluation period to our customers. During this period they can access our capability to realize the aim of the project, our qualification and how Micar21 meets these criteria. For future information don't hesitate to contact us and discuss your scientific or industrial project! ....

Read More
09/09/2015 Micar21

New Publication! Molecular dynamics simulation of the human estrogen receptor alpha: contribution to the pharmacophore of the agonists

Human estrogen receptor alpha (View the MathML source) is one of the most studied targets for in silico screening of bioactive compounds. The estrogenic activity of a vast number of chemicals has been studied for their potentially adverse effects on the hormone regulation of the endocrine system ....

Read More
03/07/2015 Micar21

New Publication! Structural and Dynamical Insight into PPARγ Antagonism: In silico Study of the Ligand-Receptor Interactions of non-Covalent Antagonists

A new paper has been published by the Micar21 team, which reveal, for the first time, how the famous PPARγ receptor looks in its antagonist form. This is an initial study of the PPARγ antagonist structure and a second, and more detail paper, is on the way to be published. ....

Read More
16/04/2015 Micar21

New Publication! Activation helix orientation of estrogen receptor is mediated by receptor dimerization: evidence from molecular dynamics simulations (Apr. 2015)

In the recent years the nuclear receptors (NR) dynamics have been extensively studied by various approaches. However, the transition path of helix 12 (H12) to an agonist or an antagonist conformation and the exchange pathway between these states is not clear yet. A number of accelerated molecular dynamics (aMD) runs were performed on both an ERα monomer and a homodimer with a total length of 2.6 µs. ....

Read More
10/02/2015 Micar21

New! A pioneering study focused on the prevention of hypertrophic cardiomyopathy (HCM) among individuals with a sarcomere gene mutation (Feb. 2015)

A pioneering clinical study, published in the Journal of American College of Cardiology, once again raises the question: Why Should Cardiologists Consider Genetic Testing for Hypertrophic Cardiomyopathy? ....

Read More
30/01/2015 Micar21

Micar 21 Ltd started to provide to our customers discovery of novel active substances for medicinal cosmetics development.

However, we also screen databases including natural chemicals extracted from plants. These are substances mainly from traditional Chinese and Indian medicine as well as many chemicals extracted from plants recognized as effective herbs in Africa, Europe and worldwide.

We offer solely new unique substances, which can be patented, tested and brought into new innovative medicinal cosmetic products....

Read More